Shots: The two studies of AZD7442 will enroll ~6,000 adults for the prevention of COVID-19 in and outside the US, expected to begin in next wk. with additional trials enrolling […]readmore
Tags : antibody
Shots: AstraZeneca has licensed Vanderbilt University’s coronavirus-neutralizing Abs & plans to advance a pair of these mAbs into clinical development as a combination therapy for COVID-19. The agreement follows AstraZeneca […]readmore
Shots: Eli Lilly reported that first patients have been dosed in a P-I study of LY-CoV555, the first Ab emerge from the collaboration b/w Lilly & AbCellera to create Ab […]readmore
Shots: Sorrento to get access to plasma containing anti-COVID-19 Abs for identifying and produce mAbs with neutralizing activity against SARS-CoV-2. The company expects to commence the P-I study of triple […]readmore
Shots: The collaboration leverages Sorrento’s mAb against SARS-CoV-2 virus that will be encoded into a gene for delivery utilizing SmartPharm’s non-viral nanoparticle platform The companies are expected to develop a […]readmore
Shots: Alligator to receive ~52M in development milestones including $1M up front, $90M as option fee and royalties on sales and share of sub-license revenue. Biotheus to get right to […]readmore
Shots: Xencor to receive an upfront, development, regulatory & commercialization milestones and royalties on sales of product. Astellas to get exclusive WW license to develop and commercialize bispecific mAb for […]readmore
Shots: AbCellera to receive technology access fee, funding, milestones, and royalties on sales of products. Novartis to get rights to license AbCellera’s technology for its 10 unknown targets Additionally, AbCellera […]readmore
Shots: Alexion to acquire Syntimmune for $1.2B in cash, including an upfront payment of $400M, with additional milestone payments of up to $800M. The transaction is expected to close in […]readmore